Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
复制标题
ofatumumab 对具有低 CD20 蛋白表达的利妥昔单抗耐药 B-CLL/SLL 细胞的功效。
DOI：
10.1111/bjh.12857
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Kiyoi H.
中科院分区：
文献类型：
--
作者：
Shimada K;Tomita A;Saito S;Kiyoi H.
本文重点介绍了奥法木单抗对具有低 CD20 蛋白表达的利妥昔单抗耐药 B-CLL/SLL 细胞的功效相关的研究。讨论的主题包括一名被诊断患有 B-CLL/SLL 的 78 岁女性接受了五年重复含利妥昔单抗化疗的案例研究、使用奥法木单抗的影响以及使用利妥昔单抗治疗 B 细胞淋巴瘤患者的临床结果。
The article focuses on a study related to the efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells having low CD20 protein expression. Topics discussed include a case study of a 78-year-old female diagnosed with B-CLL/SLL who underwent repetitive rituximab-containing chemotherapy for five years, the impact of using ofatumumab and clinical outcomes of patients with B-cell lymphoma using rituximab.